[go: up one dir, main page]

RU2003127718A - Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости - Google Patents

Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости Download PDF

Info

Publication number
RU2003127718A
RU2003127718A RU2003127718/15A RU2003127718A RU2003127718A RU 2003127718 A RU2003127718 A RU 2003127718A RU 2003127718/15 A RU2003127718/15 A RU 2003127718/15A RU 2003127718 A RU2003127718 A RU 2003127718A RU 2003127718 A RU2003127718 A RU 2003127718A
Authority
RU
Russia
Prior art keywords
flumazenil
drug
use according
dependence
treatment
Prior art date
Application number
RU2003127718/15A
Other languages
English (en)
Other versions
RU2322985C2 (ru
Inventor
ИБАНЕС Хуан Хосе ЛЕГАРДА (ES)
ИБАНЕС Хуан Хосе ЛЕГАРДА
Original Assignee
Хитиям, Инк. (Us)
Хитиям, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хитиям, Инк. (Us), Хитиям, Инк. filed Critical Хитиям, Инк. (Us)
Publication of RU2003127718A publication Critical patent/RU2003127718A/ru
Application granted granted Critical
Publication of RU2322985C2 publication Critical patent/RU2322985C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Claims (10)

1. Применение флумазенила для производства лекарственного средства для лечения кокаиновой зависимости.
2. Применение по п.1, в котором лекарственное средство вводится последовательно через интервалы времени от 1 до 15 мин, обеспечивая введение от 0,1 до 0,3 мг флумазенила.
3. Применение по п.2, в котором лекарственное средство обеспечивает от 1,5 до 2,5 мг флумазенила в сутки.
4. Применение по п.2, в котором лекарственное средство обеспечивает введение 0,2 мг флумазенила.
5. Применение по п.2, в котором лекарственное средство вводится последовательно через интервалы времени 3 мин.
6. Применение по п.2, в котором лекарственное средство обеспечивает 2 мг флумазенила в сутки.
7. Применение по п.2, в котором лекарственное средство вводится перорально или парентерально.
8. Применение по п.2, в котором лекарственное средство вводится внутривенно.
9. Применение флумазенила для приготовления лекарственного средства для лечения кокаиновой зависимости, в котором лекарственное средство обеспечивает 0,2 мг флумазенила и вводится последовательно через интервалы времени 3 мин до обеспечения приблизительно 2 мг флумазенила в сутки.
10. Лекарственное средство для лечения кокаиновой зависимости, включающее дозу приблизительно 0,2 мг флумазенила.
RU2003127718/15A 2001-02-15 2002-02-08 Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости RU2322985C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200100342 2001-02-15
ES200100342 2001-02-15

Publications (2)

Publication Number Publication Date
RU2003127718A true RU2003127718A (ru) 2005-01-27
RU2322985C2 RU2322985C2 (ru) 2008-04-27

Family

ID=8496743

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003127718/15A RU2322985C2 (ru) 2001-02-15 2002-02-08 Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости

Country Status (20)

Country Link
US (2) US7186711B2 (ru)
EP (1) EP1378267B1 (ru)
JP (2) JP4272885B2 (ru)
KR (1) KR100712571B1 (ru)
CN (1) CN1327843C (ru)
AT (1) ATE363923T1 (ru)
AU (1) AU2002231811B2 (ru)
BR (1) BR0207866A (ru)
CA (1) CA2436511C (ru)
CY (1) CY1106845T1 (ru)
DE (1) DE60220512T2 (ru)
DK (1) DK1378267T3 (ru)
ES (1) ES2287255T3 (ru)
IL (1) IL157144A0 (ru)
MX (1) MXPA03007281A (ru)
NZ (1) NZ528164A (ru)
PT (1) PT1378267E (ru)
RU (1) RU2322985C2 (ru)
UA (1) UA79586C2 (ru)
WO (1) WO2002064213A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
ES2287255T3 (es) * 2001-02-15 2007-12-16 Hythiam, Inc. Uso de flumazenil para producir un medicamento parta el tratamiento de la dependencia a cocaina.
US20080207601A1 (en) * 2005-04-07 2008-08-28 Hythiam , Inc. Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence
US7855196B2 (en) 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
ES2289935B1 (es) * 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
WO2009027564A1 (es) * 2007-08-08 2009-03-05 Legarda Ibanez Juan Jose Uso y métodos de uso de un antagonista del receptor (5-ht3) de la serotonina3 y un modulador selectivo de los canales de cloruro para el tratamiento de la adicción a o la dependencia de fármacos/drogas o trastornos del sistema nervioso central
US9396280B2 (en) * 2008-06-23 2016-07-19 Microsoft Technology Licensing, Llc Command driven web site browsing
EP2678320B1 (en) 2011-02-23 2018-09-19 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
WO2014113617A1 (en) 2013-01-21 2014-07-24 Innovative Finishes LLC Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
CN107115359A (zh) * 2016-02-24 2017-09-01 郑恩哲 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
GB9225859D0 (en) * 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
ES2287255T3 (es) * 2001-02-15 2007-12-16 Hythiam, Inc. Uso de flumazenil para producir un medicamento parta el tratamiento de la dependencia a cocaina.
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Also Published As

Publication number Publication date
CY1106845T1 (el) 2012-05-23
JP2008201799A (ja) 2008-09-04
RU2322985C2 (ru) 2008-04-27
WO2002064213A1 (es) 2002-08-22
DE60220512D1 (de) 2007-07-19
ES2287255T3 (es) 2007-12-16
ATE363923T1 (de) 2007-06-15
CA2436511A1 (en) 2002-08-22
HK1061817A1 (en) 2004-10-08
JP2004521904A (ja) 2004-07-22
US20060122219A1 (en) 2006-06-08
UA79586C2 (en) 2007-07-10
EP1378267A1 (en) 2004-01-07
CN1327843C (zh) 2007-07-25
CN1491125A (zh) 2004-04-21
KR20040010592A (ko) 2004-01-31
KR100712571B1 (ko) 2007-05-02
EP1378267B1 (en) 2007-06-06
NZ528164A (en) 2006-03-31
PT1378267E (pt) 2007-09-11
IL157144A0 (en) 2004-02-08
JP4272885B2 (ja) 2009-06-03
US7186711B2 (en) 2007-03-06
MXPA03007281A (es) 2005-01-25
CA2436511C (en) 2009-08-04
DK1378267T3 (da) 2007-10-08
DE60220512T2 (de) 2008-02-07
BR0207866A (pt) 2004-03-23
US20070142364A1 (en) 2007-06-21
AU2002231811B2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
ATE432289T1 (de) Glp-1 und behandlungsmethode für diabetes
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE60209511D1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
MXPA05012810A (es) Formas de dosis oral de memantina.
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
DE60019436D1 (de) Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
JP2004537500A5 (ru)
HUP0301828A2 (hu) Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására
IL194500A (en) A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
RU2002124141A (ru) Применение миртазапина для лечения расстройств сна
RU2005131578A (ru) Аплидин для лечения множественной миеломы
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
MXPA05007612A (es) Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.
CA2518205A1 (en) Use of a fibrate and orlistat for the treatment of obesity
MD2327F1 (en) Method of treatment of parodontium affections

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140209